Literature DB >> 21689088

Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease.

Karthik Ramasamy, Beth Hazel, Shameem Mahmood, Sophie Corderoy, Stephen Schey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21689088     DOI： 10.1111/j.1365-2141.2011.08754.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  14 in total

1.  Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.

Authors:  Suzanne Lentzsch; Amy O'Sullivan; Ryan C Kennedy; Mohammad Abbas; Lijun Dai; Silvana Lalo Pregja; Steve Burt; Michael Boyiadzis; G David Roodman; Markus Y Mapara; Mounzer Agha; John Waas; Yongli Shuai; Daniel Normolle; Jeffrey A Zonder
Journal:  Blood       Date:  2012-03-26       Impact factor: 22.113

2.  Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.

Authors:  Heinz Ludwig; Hedwig Kasparu; Clemens Leitgeb; Elisabeth Rauch; Werner Linkesch; Niklas Zojer; Richard Greil; Adelheid Seebacher; Ludek Pour; Adalbert Weißmann; Zdenek Adam
Journal:  Blood       Date:  2013-11-13       Impact factor: 22.113

Review 3.  Future agents and treatment directions in multiple myeloma.

Authors:  Enrique M Ocio; Constantine S Mitsiades; Robert Z Orlowski; Kenneth C Anderson
Journal:  Expert Rev Hematol       Date:  2013-12-18       Impact factor: 2.929

4.  European Myeloma Network guidelines for the management of multiple myeloma-related complications.

Authors:  Evangelos Terpos; Martina Kleber; Monika Engelhardt; Sonja Zweegman; Francesca Gay; Efstathios Kastritis; Niels W C J van de Donk; Benedetto Bruno; Orhan Sezer; Annemiek Broijl; Sara Bringhen; Meral Beksac; Alessandra Larocca; Roman Hajek; Pellegrino Musto; Hans Erik Johnsen; Fortunato Morabito; Heinz Ludwig; Michele Cavo; Hermann Einsele; Pieter Sonneveld; Meletios A Dimopoulos; Antonio Palumbo
Journal:  Haematologica       Date:  2015-10       Impact factor: 9.941

Review 5.  New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG).

Authors:  E M Ocio; P G Richardson; S V Rajkumar; A Palumbo; M V Mateos; R Orlowski; S Kumar; S Usmani; D Roodman; R Niesvizky; H Einsele; K C Anderson; M A Dimopoulos; H Avet-Loiseau; U-H Mellqvist; I Turesson; G Merlini; R Schots; P McCarthy; L Bergsagel; C S Chim; J J Lahuerta; J Shah; A Reiman; J Mikhael; S Zweegman; S Lonial; R Comenzo; W J Chng; P Moreau; P Sonneveld; H Ludwig; B G M Durie; J F S Miguel
Journal:  Leukemia       Date:  2013-11-20       Impact factor: 11.528

6.  Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.

Authors:  Wolfram Pönisch; Marc Andrea; Ina Wagner; Doreen Hammerschmidt; Ute Kreibich; Andreas Schwarzer; Thomas Zehrfeld; Maik Schwarz; Cornelia Winkelmann; Sirak Petros; Anette Bachmann; Tom Lindner; Dietger Niederwieser
Journal:  J Cancer Res Clin Oncol       Date:  2012-04-13       Impact factor: 4.553

7.  Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure.

Authors:  Wolfram Pönisch; Barbara Moll; Malvina Bourgeois; Marc Andrea; Thomas Schliwa; Simone Heyn; Marion Schmalfeld; Thomas Edelmann; Cornelia Becker; Franz Albert Hoffmann; Andreas Schwarzer; Ute Kreibich; Matthias Egert; Runa Stiegler; Rainer Krahl; Yvonne Remane; Anette Bachmann; Tom Lindner; Lorenz Weidhase; Sirak Petros; Stefan Fricke; Vladan Vucinic; Haifa Al Ali; Dietger Niederwieser
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-18       Impact factor: 4.553

8.  Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response.

Authors:  Bo Cai; Hui Lyu; Jingcao Huang; Shuiliang Wang; Choon-Kee Lee; Chunji Gao; Bolin Liu
Journal:  Cancer Lett       Date:  2013-02-28       Impact factor: 8.679

9.  Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells.

Authors:  Bo Cai; Shuiliang Wang; Jingcao Huang; Choon-Kee Lee; Chunji Gao; Bolin Liu
Journal:  Am J Transl Res       Date:  2013-01-21       Impact factor: 4.060

Review 10.  Treatment of relapsed and refractory multiple myeloma.

Authors:  Pieter Sonneveld; Annemiek Broijl
Journal:  Haematologica       Date:  2016-04       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.